Production (Stage)
Channel Therapeutics Corporation
CHRO
$1.22
-$0.0065-0.53%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -58.36% | -213.53% | 744.40% | -74.00% | 150.73% |
| Gross Profit | 58.36% | 213.53% | -744.40% | 74.00% | -150.73% |
| SG&A Expenses | 11.74% | -2.83% | 31.47% | 140.80% | 101.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.17% | -52.95% | 58.57% | 126.98% | 111.46% |
| Operating Income | 5.17% | 52.95% | -58.57% | -126.98% | -111.46% |
| Income Before Tax | 23.21% | 52.30% | -19.20% | -85.84% | -165.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.21% | 52.30% | -19.20% | -85.84% | -165.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.21% | 52.30% | -19.20% | -85.84% | -165.08% |
| EBIT | 5.17% | 52.95% | -58.57% | -126.98% | -111.46% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 41.21% | 84.12% | 79.74% | 67.73% | 37.21% |
| Normalized Basic EPS | 41.21% | 84.12% | 75.40% | 67.72% | 37.21% |
| EPS Diluted | 41.21% | 84.12% | 79.74% | 67.73% | 37.21% |
| Normalized Diluted EPS | 41.21% | 84.12% | 75.40% | 67.72% | 37.21% |
| Average Basic Shares Outstanding | 30.63% | 200.46% | 488.35% | 475.76% | 322.19% |
| Average Diluted Shares Outstanding | 30.63% | 200.46% | 488.35% | 475.76% | 322.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |